Analysts Issue Forecasts for Johnson & Johnson’s Q2 2022 Earnings (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJGet Rating) – Stock analysts at SVB Leerink boosted their Q2 2022 earnings per share (EPS) estimates for Johnson & Johnson in a research report issued to clients and investors on Sunday, May 22nd. SVB Leerink analyst D. Antalffy now forecasts that the company will earn $2.70 per share for the quarter, up from their prior forecast of $2.41. SVB Leerink also issued estimates for Johnson & Johnson’s Q3 2022 earnings at $2.88 EPS, Q4 2022 earnings at $2.20 EPS, FY2022 earnings at $10.45 EPS, FY2022 earnings at $10.45 EPS, Q2 2023 earnings at $2.91 EPS, Q3 2023 earnings at $3.05 EPS and Q4 2023 earnings at $2.28 EPS.

Other equities analysts have also recently issued research reports about the stock. Credit Suisse Group lifted their price objective on shares of Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 20th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 17th. Raymond James increased their price objective on Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. The Goldman Sachs Group lifted their target price on Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a report on Tuesday, April 12th. Finally, Sanford C. Bernstein downgraded Johnson & Johnson from an “outperform” rating to a “market perform” rating and upped their target price for the company from $180.00 to $183.00 in a report on Wednesday, March 16th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $187.86.

Shares of JNJ stock opened at $181.40 on Wednesday. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39. The stock has a 50-day simple moving average of $178.81 and a 200 day simple moving average of $171.12. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The stock has a market capitalization of $477.34 billion, a P/E ratio of 24.45, a P/E/G ratio of 2.87 and a beta of 0.66.

Johnson & Johnson (NYSE:JNJGet Rating) last released its earnings results on Tuesday, April 19th. The company reported $2.67 earnings per share for the quarter, topping analysts’ consensus estimates of $2.60 by $0.07. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The firm had revenue of $23.43 billion during the quarter, compared to the consensus estimate of $23.62 billion. During the same period in the prior year, the firm posted $2.59 earnings per share. The firm’s revenue for the quarter was up 5.0% compared to the same quarter last year.

Institutional investors and hedge funds have recently modified their holdings of the stock. Family CFO Inc acquired a new stake in shares of Johnson & Johnson in the fourth quarter worth about $26,000. RE Dickinson Investment Advisors LLC lifted its holdings in Johnson & Johnson by 163.3% in the 1st quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock worth $28,000 after purchasing an additional 98 shares during the last quarter. Advanced Research Investment Solutions LLC grew its holdings in Johnson & Johnson by 200.0% during the first quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock valued at $32,000 after purchasing an additional 120 shares during the last quarter. Steward Financial Group LLC bought a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $34,000. Finally, Professional Financial Advisors LLC boosted its holdings in shares of Johnson & Johnson by 47.9% during the 1st quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock worth $37,000 after buying an additional 68 shares during the period. 68.78% of the stock is currently owned by hedge funds and other institutional investors.

In other Johnson & Johnson news, insider William Hait sold 29,699 shares of the company’s stock in a transaction that occurred on Thursday, April 21st. The shares were sold at an average price of $183.58, for a total value of $5,452,142.42. Following the transaction, the insider now owns 80,236 shares in the company, valued at approximately $14,729,724.88. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Thibaut Mongon sold 23,681 shares of the business’s stock in a transaction on Thursday, March 17th. The shares were sold at an average price of $176.25, for a total transaction of $4,173,776.25. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by insiders.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 7th. Stockholders of record on Tuesday, May 24th will be given a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend yield of 2.49%. The ex-dividend date of this dividend is Monday, May 23rd. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.06. Johnson & Johnson’s dividend payout ratio (DPR) is 57.14%.

Johnson & Johnson Company Profile (Get Rating)

Johnson & Johnson researches and develops, manufactures, and sells various products in the healthcare field worldwide. It operates in three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Further Reading

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.